KOSDAQFood & Beverage311390

Neo Cremar

₩1,791▼ 4.73%2026-11-18 close
Market Cap
₩22.5B
Turnover
₩51,203,115
Volume
30K
Shares out.
12.6M
PER
—
PBR
0.3×
EPS
-₩19
Dividend Yield
2.66%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Export recovery and profit turnaround on a short earnings record

Neo Cremar turned operating profit positive in 2025 on DNF-10 export recovery, but a net loss attributable to controlling shareholders reappeared in the third quarter of 2026, so earnings durability is still being tested.

  1. 1

    On DART filings, 2025 revenue reached KRW 81.9 billion, up for a second straight year, and operating profit of KRW 5.41 billion turned positive.

  2. 2

    Third-quarter 2026 operating profit was KRW 1.08 billion, up 134.1% from a year earlier, while the net loss attributable to controlling shareholders was KRW 1.54 billion.

  3. 3

    The cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 239 million, so no PER is calculated for that period.

  4. 4

    DNF-10 was named a 2026 World Class Product, and the joint clinical result in European subjects is expected by the end of 2026.

  5. 5

    Bull factors such as export reorders and a pending clinical readout coexist with bear factors such as quarterly revenue swings and controlling-shareholder losses.

02

Business structure

Neo Cremar is a functional food ingredient company that manufactures functional sugars and peptide materials and distributes food additives. Its core product is DNF-10, a self-developed appetite-control peptide material that the company says it has produced since 2008. The material holds a U.S.

FDA GRAS no-objection letter (May 2023), Non-GMO certification, and individually recognized raw material status from the Ministry of Food and Drug Safety.

Overseas customers are the key demand base, and press reports say the product has ranked first in the diet ingredient category in Japan for three straight years since supply began in 2014. Since 2017 the company has worked with Europe-based nutraceutical firm Biotexia to expand into the U.S. and Europe.

Domestically, it supplies galactooligosaccharide (GOS) to dairy companies including Maeil Dairies. Its subsidiary BBC, consolidated in September 2024, is one of the drivers the company cited for second-quarter 2026 improvement.

The company said cumulative first-half 2025 exports reached KRW 6.3 billion, up 289% year on year. In the second quarter of 2026, reorders from major North American and Asian customers pushed core-material exports back toward normal levels. The company is positioning DNF-10 as a weight-management material for the GLP-1 era.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.1B₩500M2.6%
2025Q4₩21.6B-₩1.1B−5.0%
2026Q1₩19.1B₩700M3.5%
2026Q2₩22.8B₩3.5B15.5%
2026Q3₩18.7B₩1.1B5.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩26.7T₩1.4T-₩1.8T5.3%−3.8%62.1%
2023₩24.9B₩300M-₩5B1.1%−12.8%83.1%
2024₩40.3B-₩700M₩600M−1.7%0.8%24.7%
2025₩81.9B₩5.4B₩3B6.6%4.1%24.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a consolidated basis from DART annual reports, 2023 revenue was KRW 24.9 billion, operating profit KRW 279 million, and net loss attributable to controlling shareholders KRW 4.96 billion, marking the trough.

In 2024 revenue rose 62.1% to KRW 40.3 billion, but the company swung to an operating loss of KRW 691 million, while net income attributable to controlling shareholders turned positive at KRW 589 million.

In 2025 revenue rose 103.3% to KRW 81.9 billion, the second straight annual increase, and operating profit turned positive at KRW 5.41 billion.

Net income attributable to controlling shareholders reached KRW 2.98 billion, up 406.4%, while net income including non-controlling interests was KRW 5.17 billion, a larger figure that reflects profit allocated to non-controlling interests. Operating margin moved from 1.1% in 2023 to -1.7% in 2024 and 6.6% in 2025.

Operating cash flow rose from KRW 2.27 billion in 2023 and KRW 1.09 billion in 2024 to KRW 15.7 billion in 2025. The 2022 figures in the filing table are on a different scale from the 2023 to 2025 series and are excluded from the comparison here.

On a quarterly basis, revenue of KRW 18.1 billion and operating profit of KRW 462 million in the third quarter of 2025 were followed by a fourth-quarter operating loss of KRW 1.08 billion on revenue of KRW 21.6 billion.

The first quarter of 2026 posted revenue of KRW 19.1 billion, down 11.8% from the prior quarter, and operating profit of KRW 666 million, a swing back to profit.

The second quarter of 2026 delivered revenue of KRW 22.8 billion and operating profit of KRW 3.54 billion, which the company said were record quarterly results.

Third-quarter 2026 revenue was KRW 18.7 billion, down 17.9% from the prior quarter and up 3.8% year on year, and operating profit was KRW 1.08 billion, up 134.1% year on year, yet the company swung to a net loss of KRW 1.54 billion attributable to controlling shareholders.

Why operating profit and controlling-shareholder earnings moved in opposite directions is a point to examine in the non-operating and tax lines. The cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 239 million.

05

Industry analysis

The weight-management ingredient market is gaining attention for functional materials that address appetite control and satiety, alongside the spread of GLP-1 class obesity drugs. Neo Cremar positions its product as a representative weight-management material for the GLP-1 era.

Whether drug diffusion will lift demand for supporting ingredients or act as a substitute is not yet clear, and clinical results and customer order trends will be the variables that answer that question.

In cycle terms, the company is in a phase of export recovery that followed its return to profit in 2024 and continued through the first half of 2026. Whether reorders from major customers continue is the checkpoint that determines if the export normalization lasts.

On competition, DNF-10's production history since 2008, its FDA GRAS letter, Non-GMO certification and Korean raw material recognition are presented as differentiators. Press reports of a first-place ranking in Japan's diet ingredient category serve as evidence of overseas validation.

Functional labeling and approval timelines in Europe and the U.S., however, move at different speeds depending on national rules. Unlike consumer-facing food companies in the same sector, Neo Cremar sells ingredients to business customers, so customer orders directly drive its results.

06

Outlook

The company has identified three datable milestones. First, the joint clinical study with Biotexia in European subjects, which is testing satiety and appetite-suppression effects, is expected to produce results by the end of 2026.

Second, the company plans to start full-scale supply in Europe from 2027 based on those results. Third, it is pursuing local registration in Australia and Brazil, though no timing has been fixed.

The company has set expanded global approvals for its third-generation functional materials and deeper strategic partnerships as direction. When it reported second-quarter 2026 results, the company attributed record quarterly performance to export recovery and subsidiary growth.

On the positive side, favorable clinical results would give the European supply plan a concrete basis. On the negative side, results short of expectations could delay the 2027 European timeline or narrow its scope.

On earnings, the third-quarter 2026 net loss attributable to controlling shareholders makes the full-year direction of that line the next checkpoint. The 2026 annual report will confirm full-year operating margin and net income attributable to controlling shareholders in filed figures. Fourth-quarter 2026 results have not yet been filed in a periodic report.

07

Valuation

PER
—
PBR
0.3×
ROE
-0.3%
EPS
-₩19
BPS
₩5,868
Dividend per share
₩50

Price-to-book ratio sits well below 1x. Quarter-end price-to-book ratios moved roughly around 1x from September 2024 through September 2025, so the current level is low relative to net assets compared with that range.

However, controlling-shareholder equity is about half of total equity, so non-controlling interests need to be considered when reading net asset value. PER cannot be calculated on the last four quarters because of the cumulative net loss attributable to controlling shareholders.

On a full-year 2025 basis controlling-shareholder net income was positive, but quarterly swings are large, so the reading of the multiple depends on the period chosen. Cash dividends were recorded at zero from 2018 through 2022, so the dividend record is short.

Dividend yield should therefore be read against the recent payout history. Comparisons with industry averages are meaningful only when the periods and definitions match.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Overseas demand and World Class Product recognition

Neo Cremar said DNF-10 was named a 2026 World Class Product, an award run by the Ministry of Trade, Industry and Energy and KOTRA, on 18 November 2026. According to the company, cumulative first-half 2025 exports reached KRW 6.3 billion, up 289% year on year.

Reorders from North American and Asian customers expanded in the second quarter of 2026, which the company said returned exports toward normal.

Two straight years of revenue growth and margin recovery

Revenue rose to KRW 40.3 billion in 2024 and KRW 81.9 billion in 2025, two consecutive annual increases, and operating profit turned positive at KRW 5.41 billion in 2025. Operating margin improved from 1.1% in 2023 to 6.6% in 2025.

Third-quarter 2026 operating profit of KRW 1.08 billion, up 134.1% year on year, kept the profit trend in place.

European clinical study and 2027 supply plan

The joint clinical study with Biotexia in European subjects is expected to produce results by the end of 2026. The company said it will begin full-scale European supply in 2027 based on those results and is pursuing approvals in Australia and Brazil. Favorable results would give the overseas expansion plan a concrete basis.

09

Bear factors

Swing to a controlling-shareholder net loss

The net loss attributable to controlling shareholders in the third quarter of 2026 was KRW 1.54 billion, a swing into loss from a year earlier. Operating profit was positive in the same quarter, but the controlling-shareholder line was negative, so operating-level profit did not carry through to net income.

The cumulative net loss over the last four quarters is KRW 239 million, and quarterly results vary widely compared with full-year 2025 controlling-shareholder net income of KRW 2.98 billion.

Large swings in quarterly revenue

Fourth-quarter 2025 revenue of KRW 21.6 billion rose 19.9% from the prior quarter, yet the quarter posted an operating loss of KRW 1.08 billion. First-quarter 2026 revenue of KRW 19.1 billion fell 11.8% from the prior quarter, and third-quarter 2026 revenue of KRW 18.7 billion fell 17.9%. Because quarterly revenue moves this sharply, the stability of annual results is still being tested.

A short profit record and a non-controlling share of earnings

In 2023 operating profit was only KRW 279 million and the net loss attributable to controlling shareholders was KRW 4.96 billion, and in 2024 an operating loss of KRW 691 million was recorded. Profitable results have built up only since 2025, so the earnings record is short.

In 2025 net income of KRW 5.17 billion exceeded controlling-shareholder net income of KRW 2.98 billion, so non-controlling interests take a share of profit.

10

Risk factors

Clinical and approval uncertainty

If the European clinical results fall short of expectations, the basis for the 2027 European supply plan weakens. Without a fixed timeline for approvals in Australia and Brazil, the timing of overseas sales growth is also uncertain. Until results are reported, European sales contribution is hard to reflect in earnings.

Export dependence and customer order volatility

Because exports make up a large share of sales, results are sensitive to exchange rates and to the timing of customer orders. Quarterly revenue declines in the first and third quarters of 2026 illustrate that sensitivity. Inventory adjustments or order cuts by large customers could widen quarterly swings further.

Changes in the obesity drug landscape

It is still unclear whether the spread of GLP-1 class drugs will raise demand for supporting ingredients or shift demand away from them. Functional labeling and raw material rules differ by country, and rule changes would affect sales structure.

Whether the weight-management positioning turns into real demand will be shown by clinical results and customer response.

11

What to watch next

  1. End of 2026

    Release of the joint DNF-10 clinical results in European subjects with Biotexia. Satiety and appetite-suppression data will form the basis for the European supply plan.

  2. Mid-February 2027 (estimated)

    Preliminary fourth-quarter 2026 results. This timing is estimated from the precedent of 11 February 2026 for fourth-quarter 2025 results, and the focus is the direction of operating and controlling-shareholder results.

  3. By 31 March 2027

    Filing of the 2026 annual report on DART. It will be the first periodic report that fixes full-year operating margin and net income attributable to controlling shareholders.

  4. 2027

    The start of full-scale European supply and progress on local approvals in Australia and Brazil. This will show whether overseas sales contribute visibly to earnings.

12

Overall view

Neo Cremar's revenue has grown for two straight years since its 2023 trough, and operating profit turned positive at KRW 5.41 billion in 2025, a change in its earnings structure that is still in progress.

DNF-10's selection as a 2026 World Class Product and the expansion of export reorders in the second quarter of 2026 are the main bull factors on the business side.

On the other hand, the third-quarter 2026 net loss attributable to controlling shareholders of KRW 1.54 billion and the four-quarter cumulative net loss of KRW 239 million show that earnings durability is still being tested.

Quarterly revenue has moved up and down from the fourth quarter of 2025 through the third quarter of 2026, so full-year direction will be confirmed in the 2026 annual report. On valuation, the price-to-book ratio sits well below 1x, while PER cannot be calculated on the last four quarters because of net losses.

The European clinical results due by the end of 2026 and the 2027 European supply plan are the next inflection points for expansion. Weighing bull and bear factors equally, the direction of the business turnaround is clear, but earnings stability and the overseas clinical outcome remain open.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. supple.kr
  3. news.nate.com
  4. specialtimes.co.kr
  5. cremar.co.kr
  6. supple.kr
  7. medipana.com
  8. k5.co.kr
  9. mt.co.kr
  10. m.thinkpool.com
  11. kr.investing.com
  12. newspim.com
  13. finance.yahoo.com
  14. kr.investing.com
  15. m.thinkpool.com
  16. globenewswire.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis